| __timestamp | Corcept Therapeutics Incorporated | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 18372000 | 79696000 |
| Thursday, January 1, 2015 | 15419000 | 93236000 |
| Friday, January 1, 2016 | 23844000 | 150842000 |
| Sunday, January 1, 2017 | 40376000 | 150643000 |
| Monday, January 1, 2018 | 75247000 | 150252000 |
| Tuesday, January 1, 2019 | 89017000 | 140804000 |
| Wednesday, January 1, 2020 | 114764000 | 34236000 |
| Friday, January 1, 2021 | 113864000 | 35672000 |
| Saturday, January 1, 2022 | 130991000 | 66607000 |
| Sunday, January 1, 2023 | 184353000 | 76363000 |
| Monday, January 1, 2024 | 79048000 |
Cracking the code
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Halozyme consistently allocated a significant portion of its resources to R&D, peaking in 2016 with a remarkable 150% increase compared to 2014. However, a notable decline occurred in 2020, with spending dropping by over 75% from its peak. In contrast, Corcept's R&D expenditure has shown a steady upward trajectory, culminating in a 900% increase by 2023 compared to 2014.
This divergence highlights Halozyme's initial aggressive investment strategy, while Corcept's gradual increase suggests a more sustained commitment to innovation. As the biotech sector continues to grow, these spending patterns offer valuable insights into each company's strategic priorities.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and Corcept Therapeutics Incorporated Allocate Funds
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Lantheus Holdings, Inc. or Corcept Therapeutics Incorporated: Who Invests More in Innovation?
Comparing Innovation Spending: Corcept Therapeutics Incorporated and Opthea Limited
Research and Development Investment: Corcept Therapeutics Incorporated vs Alkermes plc
Who Prioritizes Innovation? R&D Spending Compared for Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
Research and Development: Comparing Key Metrics for Corcept Therapeutics Incorporated and Veracyte, Inc.